Dr. Benjamin N. Breyer

What excites me about that is just the concept of medicine applied to a stricture.

I don't know if Paxitaxel is the right medicine, but what I would love to see are companies

using all these different molecules.

Maybe it's AI that we find the next perfect molecule.

Can we do it associated with disease state?

Can you have an LS balloon or, you know, this is for radiation?

Like these are different milieus, they're not the same.

Yeah, I agree.

You know, I think we just don't

have a full comprehension of why strictures form and how, how to best treat them.

I think that the urethroplasty is a highly successful surgery.

It's not perfect.

People get through it relatively smoothly, but it's, it's not a total walk in the park for everybody.

You know, I do think some of the work done by Brad Erickson through the Terns Group around phenotyping strictures so that we can have, you know, I think criticism of it, it's maybe overly complicated, but what I really like about it is that you can have an apples to apples comparison and discussions, at least in the setting of an academic meeting or in the setting of a clinical trial or a paper.

because not every structure is the same and not every bobar structure is the same.

And when you really dig into the weeds and Brad did, it's actually quite nuanced and complicated, but I think having that as a footing will help us better understand pathophysiology because we can actually talk about things cogently.

I love this idea of minimally invasive.

Nick Warner's a real innovator at Mayo doing these minimally invasive techniques.

I do think besides pathophysiology and potentially medicines,

There's going to be instrumentation and different technical things that are produced.